Guidance

Shingles vaccine (Zostavax®): patient group direction (PGD) template

PGD template to support the national shingles (Zostavax®) vaccination programme for eligible adults.

• From: Public Health England
• Published: 14 July 2015
• Last updated: 8 March 2021, see all updates

Documents

Shingles vaccine (Zostavax®) PGD template

Ref: PHE publications gateway number: GW-1989 MS Word Document, 140KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the administration of shingles (herpes zoster, live) vaccine in accordance with the national shingles (herpes zoster) immunisation programme.

It is valid from 1 April 2021 to 31 March 2023.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 14 July 2015
Last updated 8 March 2021 + show all updates

1. 8 March 2021

   Added version 09.00 - see page 2 for change history.

2. 11 March 2019

   Added version V08.00 - updated as routine review prior to PGD expiry (see document change history).

3. 8 August 2017

   Revised document to correct inclusion criteria date from 2013 to 2012 and add DOB note.

4. 17 May 2017

   Updated patient group direction template to allow vaccination from turn of age 70 or 78

5. 23 August 2016

   Updated patient group direction template valid up to 31 August 2017

6. 24 February 2016

   Updated PGD to allow for intramuscular administration (in line with the amended product license).

7. 19 November 2015

   Updated the shingles PGD to include detailed information on the use of the shingles vaccine in immunosuppressed individuals.

8. 14 July 2015

   First published.